AAAAAA

   
Results: 1-17 |
Results: 17
CONVENTIONAL COMPARED WITH INDIVIDUALIZED CHEMOTHERAPY FOR CHILDHOOD ACUTE LYMPHOBLASTIC-LEUKEMIA
Authors: EVANS WE RELLING MV RODMAN JH CROM WR BOYETT JM PUI CH
Citation: We. Evans et al., CONVENTIONAL COMPARED WITH INDIVIDUALIZED CHEMOTHERAPY FOR CHILDHOOD ACUTE LYMPHOBLASTIC-LEUKEMIA, The New England journal of medicine, 338(8), 1998, pp. 499-505
PROBENECID ALTERS TOPOTECAN SYSTEMIC AND RENAL DISPOSITION BY INHIBITING RENAL TUBULAR SECRETION
Authors: ZAMBONI WC HOUGHTON PJ JOHNSON RK HULSTEIN JL CROM WR CHESHIRE PJ HANNA SK RICHMOND LB LUO XL STEWART CF
Citation: Wc. Zamboni et al., PROBENECID ALTERS TOPOTECAN SYSTEMIC AND RENAL DISPOSITION BY INHIBITING RENAL TUBULAR SECRETION, The Journal of pharmacology and experimental therapeutics, 284(1), 1998, pp. 89-94
A PHASE-II TRIAL OF HIGH-DOSE METHOTREXATE IN PREVIOUSLY UNTREATED CHILDREN AND ADOLESCENTS WITH HIGH-RISK UNRESECTABLE OR METASTATIC RHABDOMYOSARCOMA
Authors: PAPPO AS BOWMAN LC FURMAN WL RAO BN KUN LE JENKINS JJ CROM WR LUO XL KASTE SC AVERY L MEYER WH SHAPIRO DN CRIST WM
Citation: As. Pappo et al., A PHASE-II TRIAL OF HIGH-DOSE METHOTREXATE IN PREVIOUSLY UNTREATED CHILDREN AND ADOLESCENTS WITH HIGH-RISK UNRESECTABLE OR METASTATIC RHABDOMYOSARCOMA, Journal of pediatric hematology/oncology, 19(5), 1997, pp. 438-442
DISPOSITION OF IRINOTECAN AND SN-38 FOLLOWING ORAL AND INTRAVENOUS IRINOTECAN DOSING IN MICE
Authors: STEWART CF ZAMBONI WC CROM WR HOUGHTON PJ
Citation: Cf. Stewart et al., DISPOSITION OF IRINOTECAN AND SN-38 FOLLOWING ORAL AND INTRAVENOUS IRINOTECAN DOSING IN MICE, Cancer chemotherapy and pharmacology, 40(3), 1997, pp. 259-265
PROBENECID ALTERS TOPOTECAN (TPT) SYSTEMIC AND RENAL DISPOSITION
Authors: ZAMBONI WC HOUGHTON PJ JOHNSON RK HULSTEIN JL CROM WR CHESHIRE PJ RICHMOND LB STEWART CF
Citation: Wc. Zamboni et al., PROBENECID ALTERS TOPOTECAN (TPT) SYSTEMIC AND RENAL DISPOSITION, Clinical pharmacology and therapeutics, 61(2), 1997, pp. 33-33
CEREBROSPINAL-FLUID PHARMACOKINETICS AND PENETRATION OF CONTINUOUS-INFUSION TOPOTECAN IN CHILDREN WITH CENTRAL-NERVOUS-SYSTEM TUMORS
Authors: BAKER SD HEIDEMAN RL CROM WR KUTTESCH JF GAJJAR A STEWART CF
Citation: Sd. Baker et al., CEREBROSPINAL-FLUID PHARMACOKINETICS AND PENETRATION OF CONTINUOUS-INFUSION TOPOTECAN IN CHILDREN WITH CENTRAL-NERVOUS-SYSTEM TUMORS, Cancer chemotherapy and pharmacology, 37(3), 1996, pp. 195-202
TOPOISOMERASE-I INTERACTIVE DRUGS IN CHILDREN WITH CANCER
Authors: STEWART CF ZAMBONI WC CROM WR GAJJAR A HEIDEMAN RL FURMAN WL MEYER WH HOUGHTON PJ PRATT CB
Citation: Cf. Stewart et al., TOPOISOMERASE-I INTERACTIVE DRUGS IN CHILDREN WITH CANCER, Investigational new drugs, 14(1), 1996, pp. 37-47
HEPATIC DRUG CLEARANCE IN PATIENTS WITH MILD CYSTIC-FIBROSIS
Authors: KEARNS GL CROM WR KARLSON KH MALLORY GB EVANS WE
Citation: Gl. Kearns et al., HEPATIC DRUG CLEARANCE IN PATIENTS WITH MILD CYSTIC-FIBROSIS, Clinical pharmacology and therapeutics, 59(5), 1996, pp. 529-540
INTERPATIENT VARIABILITY IN ORAL (PO) ABSORPTION OF TOPOTECAN (TPT) IN CHILDREN WITH RELAPSED SOLID TUMORS
Authors: ZAMBONI WC CROM WR BOWMAN LC PRATT CB HOUGHTON PJ STEWART CF
Citation: Wc. Zamboni et al., INTERPATIENT VARIABILITY IN ORAL (PO) ABSORPTION OF TOPOTECAN (TPT) IN CHILDREN WITH RELAPSED SOLID TUMORS, Clinical pharmacology and therapeutics, 59(2), 1996, pp. 42-42
LIVER VOLUME AS A DETERMINANT OF DRUG CLEARANCE IN CHILDREN AND ADOLESCENTS
Authors: MURRY DJ CROM WR REDDICK WE BHARGAVA R EVANS WE
Citation: Dj. Murry et al., LIVER VOLUME AS A DETERMINANT OF DRUG CLEARANCE IN CHILDREN AND ADOLESCENTS, Drug metabolism and disposition, 23(10), 1995, pp. 1110-1116
CLINICAL PHARMACODYNAMICS OF CONTINUOUS-INFUSION TOPOTECAN IN CHILDREN - SYSTEMIC EXPOSURE PREDICTS HEMATOLOGIC TOXICITY
Authors: STEWART CF BAKER SD HEIDEMAN RL JONES D CROM WR PRATT CB
Citation: Cf. Stewart et al., CLINICAL PHARMACODYNAMICS OF CONTINUOUS-INFUSION TOPOTECAN IN CHILDREN - SYSTEMIC EXPOSURE PREDICTS HEMATOLOGIC TOXICITY, Journal of clinical oncology, 12(9), 1994, pp. 1946-1954
PATIENT CHARACTERISTICS ASSOCIATED WITH HIGH-RISK METHOTREXATE CONCENTRATIONS AND TOXICITY
Authors: RELLING MV FAIRCLOUGH D AYERS D CROM WR RODMAN JH PUI CH EVANS WE
Citation: Mv. Relling et al., PATIENT CHARACTERISTICS ASSOCIATED WITH HIGH-RISK METHOTREXATE CONCENTRATIONS AND TOXICITY, Journal of clinical oncology, 12(8), 1994, pp. 1667-1672
PHARMACOKINETICS IN THE CHILD
Authors: CROM WR
Citation: Wr. Crom, PHARMACOKINETICS IN THE CHILD, Environmental health perspectives, 102, 1994, pp. 111-117
PHARMACOKINETICS OF VINCRISTINE IN CHILDREN AND ADOLESCENTS WITH ACUTE LYMPHOCYTIC-LEUKEMIA
Authors: CROM WR DEGRAAF SSN SYNOLD T UGES DRA BLOEMHOF H RIVERA G CHRISTENSEN ML MAHMOUD H EVANS WE
Citation: Wr. Crom et al., PHARMACOKINETICS OF VINCRISTINE IN CHILDREN AND ADOLESCENTS WITH ACUTE LYMPHOCYTIC-LEUKEMIA, The Journal of pediatrics, 125(4), 1994, pp. 642-649
PHARMACOKINETICS OF CLADRIBINE (2-CHLORODEOXYADENOSINE) IN CHILDREN WITH ACUTE-LEUKEMIA
Authors: KEARNS CM BLAKLEY RL SANTANA VM CROM WR
Citation: Cm. Kearns et al., PHARMACOKINETICS OF CLADRIBINE (2-CHLORODEOXYADENOSINE) IN CHILDREN WITH ACUTE-LEUKEMIA, Cancer research, 54(5), 1994, pp. 1235-1239
COMPLETE HEMATOLOGIC REMISSIONS INDUCED BY 2-CHLORODEOXYADENOSINE IN CHILDREN WITH NEWLY-DIAGNOSED ACUTE MYELOID-LEUKEMIA
Authors: SANTANA VM HURWITZ CA BLAKLEY RL CROM WR LUO XL ROBERTS WM RIBEIRO R MAHMOUD H KRANCE RA
Citation: Vm. Santana et al., COMPLETE HEMATOLOGIC REMISSIONS INDUCED BY 2-CHLORODEOXYADENOSINE IN CHILDREN WITH NEWLY-DIAGNOSED ACUTE MYELOID-LEUKEMIA, Blood, 84(4), 1994, pp. 1237-1242
SATURABLE ELIMINATION AND SATURABLE PROTEIN-BINDING ACCOUNT FOR FLAVONE ACETIC-ACID PHARMACOKINETICS
Authors: RELLING MV EVANS RR GROOM S CROM WR PRATT CB
Citation: Mv. Relling et al., SATURABLE ELIMINATION AND SATURABLE PROTEIN-BINDING ACCOUNT FOR FLAVONE ACETIC-ACID PHARMACOKINETICS, Journal of pharmacokinetics and biopharmaceutics, 21(6), 1993, pp. 639-651
Risultati: 1-17 |